AbbVie Reports P-III (CLL14) and (MURANO) Studies Results of Venclyxto/ Venclexta (venetoclax) for Chronic Lymphocytic Leukemia
Shots:
- The P-III study (CLL14) evaluating Venclyxto/Venclexta & obinutuzumab vs obinutuzumab & chlorambucil in 432 patients while the P-III trial (MURANO) evaluating Venclyxto/Venclexta & rituximab vs bendamustine & rituximab in 389 patients
- Both studies' results showed the long-term benefits of fixed-duration venetoclax combinations. The 6yr. follow-up results from the (CLL14) study showed improved PFS & higher rates of uMRD (53.1% vs 21.7%), improved rates of TTNT (65.2% vs 37.1%), differences in PFS & TTNT benefits were maintained across all risk groups with no new safety signals
- In the (MURANO) trial, m-PFS (54.7 vs 17.0mos.) after 7yr. of median follow-up, 7yr. OS rates (69.6% vs 51%), patients achieved uMRD (70.3%), and those patients were shown to have improved PFS & OS over patients with detectable MRD (29.7%)
Ref: AbbVie | Image: AbbVie
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
